Anti-fibrotic activity of Euglena gracilis and paramylon in a mouse model of non-alcoholic steatohepatitis

被引：23

作者：

Nakashima, Ayaka ^{[1
]}

Sugimoto, Ryota ^{[1
]}

Suzuki, Kengo ^{[1
]}

Shirakata, Yuka ^{[2
]}

Hashiguchi, Taishi ^{[2
]}

Yoshida, Chikara ^{[2
]}

Nakano, Yoshihisa ^{[3
]}

机构：

[1] Euglena Co Ltd, Tokyo, Japan

[2] SMC Labs Inc, Tokyo, Japan

[3] Osaka Prefecture Univ, Ctr Res & Dev Bioresources, Osaka, Japan

来源：

FOOD SCIENCE & NUTRITION | 2019年 / 7卷 / 01期

关键词：

Euglena; fibrosis; microalgae; NASH; Paramylon; FATTY LIVER-DISEASE; NATURAL-HISTORY; FERMENTATION; ASSOCIATION; MANAGEMENT;

D O I：

10.1002/fsn3.828

中图分类号：

TS2 [食品工业];

学科分类号：

0832 ;

摘要：

Progression to non-alcoholic steatohepatitis (NASH) manifests as hepatitis, fibrosis, and sometimes carcinoma, resulting in liver failure. Various clinical trials have indicated that several pharmacological agents, including angiotensin II receptor blockers (ARBs) or farnesoid X receptor (FXR) agonists, are effective in NASH treatment. In addition, functional foods are expected to be important alternatives for treating or preventing NASH. Recently, focus has been directed toward microalgae as dietary supplements, mainly for lifestyle-related diseases, because they contain various nutrients and functional ingredients. Specifically, a unicellular microalga Euglena gracilis stores a unique beta-1,3-glucan particle called paramylon that stimulates the immune system. In this study, we evaluated the effects of Euglena and paramylon on NASH in Stelic Animal Model (STAM) mice using Sirius red staining and confirmed that oral administration of Euglena or paramylon inhibits the process of liver fibrosis. Moreover, compared with controls, paramylon decreased non-alcoholic fatty liver disease (NAFLD) activity scores related to inflammation. These results indicate that the oral administration of Euglena and paramylon inhibits fibrosis and ameliorates NASH.

引用

页码：139 / 147

页数：9